VAD regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}}VAD Regimen; Vincristine-Adriamycin-Dexamethasone Regimen ==Overview== {{PAGENAME}} refers to a regimen consisting of vincri..." |
No edit summary |
||
| Line 4: | Line 4: | ||
{{SK}}VAD Regimen; Vincristine-Adriamycin-Dexamethasone Regimen | {{SK}}VAD Regimen; Vincristine-Adriamycin-Dexamethasone Regimen | ||
==Overview== | ==Overview== | ||
| Line 11: | Line 10: | ||
==Regimen== | ==Regimen== | ||
{{chemo|V|Vincristine}} | {{chemo|V|Vincristine}} | ||
{{chemo|A|Doxorubicin (Adriamycin)}} | {{chemo|A|Doxorubicin (Adriamycin)}} | ||
{{chemo|D|Dexamethasone}} | {{chemo|D|Dexamethasone}} | ||
==Indications== | ==Indications== | ||
*[[Multiple myeloma]]<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63498&ns=NCI_Thesaurus}}</ref><ref name="pmid23815915">{{cite journal| author=Wan J| title=[Therapeutic efficacy analysis of VD regimen and VAD regimen for multiple myeloma]. | journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi | year= 2013 | volume= 21 | issue= 3 | pages= 647-9 | pmid=23815915 | doi=10.7534/j.issn.1009-2137.2013.03.022 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23815915 }} </ref> | *[[Multiple myeloma]]<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63498&ns=NCI_Thesaurus}}</ref><ref name="pmid23815915">{{cite journal| author=Wan J| title=[Therapeutic efficacy analysis of VD regimen and VAD regimen for multiple myeloma]. | journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi | year= 2013 | volume= 21 | issue= 3 | pages= 647-9 | pmid=23815915 | doi=10.7534/j.issn.1009-2137.2013.03.022 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23815915 }} </ref> | ||
Latest revision as of 14:46, 30 March 2015
|
WikiDoc Resources for VAD regimen |
|
Articles |
|---|
|
Most recent articles on VAD regimen Most cited articles on VAD regimen |
|
Media |
|
Powerpoint slides on VAD regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on VAD regimen at Clinical Trials.gov Clinical Trials on VAD regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on VAD regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on VAD regimen Discussion groups on VAD regimen Patient Handouts on VAD regimen Directions to Hospitals Treating VAD regimen Risk calculators and risk factors for VAD regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for VAD regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:VAD Regimen; Vincristine-Adriamycin-Dexamethasone Regimen
Overview
VAD regimen refers to a regimen consisting of vincristine, doxorubicin (adriamycin) and dexamethasone used as induction treatment for multiple myeloma.[1][2]
Regimen
VVincristine
ADoxorubicin (Adriamycin)
DDexamethasone
Indications
References
- ↑ "NCI Thesaurus".
- ↑ 2.0 2.1 Wan J (2013). "[Therapeutic efficacy analysis of VD regimen and VAD regimen for multiple myeloma]". Zhongguo Shi Yan Xue Ye Xue Za Zhi. 21 (3): 647–9. doi:10.7534/j.issn.1009-2137.2013.03.022. PMID 23815915.
- ↑ "NCI Thesaurus".